AN2 Therapeutics, Inc. (ANTX) Stock

Understand AN2 Therapeutics, Inc.: how it makes money

AN2 Therapeutics is a clinical-stage biopharmaceutical company developing epetraborole, a once-daily oral treatment candidate for chronic non-tuberculous mycobacterial lung disease, and it is not generating revenue from product sales in the provided data.

Because AN2 is clinical-stage, its profit path depends on demonstrating epetraborole benefit versus placebo on key trial endpoints (both patient-reported response and sputum culture conversion), while successfully navigating trial execution and regulatory review.

Business quality (Weak): The available trial readouts show comparative efficacy signals for epetraborole on multiple endpoints, but the program also shows meaningful clinical and execution risk signals (including high observed mortality and trial termination after a pause).

Bull case

• Patient-reported clinical response favors epetraborole versus placebo: Patient-Reported Outcome-Based Clinical Response Rate was 39.5% for epetraborole plus Optimized Background Regimen versus 25.0% for placebo plus Optimized Background Regimen, a 13.9% treatment difference.
• Microbiologic signal also favors epetraborole at Month 6: Sputum Culture Conversion Rate at Month 6 was 13.2% for epetraborole plus Optimized Background Regimen versus 10.0% for placebo plus Optimized Background Regimen, a 3.4% treatment difference.
• Trial activity indicates meaningful enrollment footprint: The Phase 2/3 pivotal epetraborole trial shows Active Clinical Sites of 90 and Phase 3 Study Sample Size of 97.

Bear case

• Observed mortality is high: The Observed 3-Month Mortality Rate is 40.0%.
• Trial execution disruptions are evident: The dataset shows Phase 2 EBO-301 Study Patients Terminated of 80 and Phase 3 EBO-301 Study Patients Enrolled Prior to Pause (to be Terminated) of 97, indicating a pause with subsequent termination of patients.
• Operating losses remain severe in the latest provided period: For the period ending 2026-03-31, operating margin is -2017.4, and revenue is 0.0B in the provided data.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Organogenesis Holdings Inc. (ORGO)
• Minerva Neurosciences, Inc. (NERV)
• Avidity Biosciences, Inc. (RNA)
• Immunic, Inc. (IMUX)
• Keros Therapeutics, Inc. (KROS)
• SIGA Technologies, Inc. (SIGA)
• PepGen Inc. (PEPG)
• Journey Medical Corporation (DERM)